ADRB2 and cancer: Among β-ARs, β2-AR is considered the principal receptor subtype involved in the modulation of catecholamine effect in cancer (77), and it may explain why non-selective β-AR blockers (acting on β1- and β2-AR) provide protection against different types of cancer (78–80).